Current status and future expectations of nanobodies in oncology trials
INTRODUCTION: Monoclonal antibodies have revolutionized personalized medicine for cancer in recent decades. Despite their broad application in oncology, their large size and complexity may interfere with successful tumor targeting for certain applications of cancer diagnosis and therapy. Nanobodies have unique structural and pharmacological features compared to monoclonal antibodies and have successfully been used as complementary anti-cancer diagnostic and/or therapeutic tools.
AREAS COVERED: Here, an overview is given of the nanobody-based diagnostics and therapeutics that have been or are currently being tested in oncological clinical trials. Furthermore, preclinical developments, which are likely to be translated into the clinic in the near future, are highlighted.
EXPERT OPINION: Overall, the presented studies show the application potential of nanobodies in the field of oncology, making it likely that more nanobodies will be clinically approved in the upcoming future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 8 vom: 19. Juli, Seite 705-721 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Pauw, Tessa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2023.2249814 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361366566 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361366566 | ||
| 003 | DE-627 | ||
| 005 | 20231226085003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2023.2249814 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361366566 | ||
| 035 | |a (NLM)37638538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Pauw, Tessa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status and future expectations of nanobodies in oncology trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Monoclonal antibodies have revolutionized personalized medicine for cancer in recent decades. Despite their broad application in oncology, their large size and complexity may interfere with successful tumor targeting for certain applications of cancer diagnosis and therapy. Nanobodies have unique structural and pharmacological features compared to monoclonal antibodies and have successfully been used as complementary anti-cancer diagnostic and/or therapeutic tools | ||
| 520 | |a AREAS COVERED: Here, an overview is given of the nanobody-based diagnostics and therapeutics that have been or are currently being tested in oncological clinical trials. Furthermore, preclinical developments, which are likely to be translated into the clinic in the near future, are highlighted | ||
| 520 | |a EXPERT OPINION: Overall, the presented studies show the application potential of nanobodies in the field of oncology, making it likely that more nanobodies will be clinically approved in the upcoming future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Nanobodies | |
| 650 | 4 | |a clinical translation | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a oncology | |
| 650 | 4 | |a single domain antibodies | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Single-Domain Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a De Mey, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Debacker, Jens M |e verfasserin |4 aut | |
| 700 | 1 | |a Raes, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Van Ginderachter, Jo A |e verfasserin |4 aut | |
| 700 | 1 | |a De Groof, Timo W M |e verfasserin |4 aut | |
| 700 | 1 | |a Devoogdt, Nick |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 8 vom: 19. Juli, Seite 705-721 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:8 |g day:19 |g month:07 |g pages:705-721 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2249814 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 8 |b 19 |c 07 |h 705-721 | ||